Streetbeat News

Products Services

LLY

The FDA is reconsidering its ban on compounding pharmacies supplying cheaper versions of Eli Lilly's weight loss and diabetes drugs. This follows a complaint from compounding groups and a shortage of Eli Lilly's tirzepatide injection, branded as Mounjaro and Zepbound.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 1:43 pm

LBPH

H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals, Inc for $60.00 per share, valuing the transaction at approximately $2.6 billion. The acquisition is expected to close in Q4 2024. Longboard's lead asset, bexicaserin, is under development for neurological diseases and has received FDA designations. The acquisition will diversify Lundbeck's revenue growth, with expected global peak sales of $1.5 billion to $2 billion.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 1:34 pm

EPOW

Sunrise New Energy Co., Ltd. (NASDAQ:EPOW) has secured $1.04 million in funding for its innovative silicon-carbon anode project, approved by the Guizhou Provincial Department of Science and Technology. The project promises significant advancements in lithium-ion battery technology.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:29 pm

FXI

VGK

The EU has received price undertaking offers from the Chinese Chamber of Commerce and separate EV exporters regarding electric vehicles. However, reaching an agreement by the end of October seems challenging. A single minimum price as an alternative to tariffs is not feasible.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:28 pm

QQQ

SBUX

SPY

Starbucks is shifting its strategy under new CEO Brian Niccol by reducing promotions and focusing on premium coffee and holiday favorites. The company aims to improve in-store experiences and reinforce its premium image amid declining sales and customer complaints. Starbucks' stock has been downgraded by Jefferies, and its third-quarter revenue lagged analyst estimates.

Portfolio Pulse from Anusuya Lahiri

October 14, 2024 | 1:23 pm

JSPR

Jasper Therapeutics Inc (NASDAQ:JSPR) stock is trading higher after reporting positive preliminary data from its SPOTLIGHT Phase 1b/2a study of briquilimab for cold urticaria and symptomatic dermographism. The study showed high clinical response rates and no serious adverse events, leading to regulatory clearance for further trials.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 1:22 pm

GENI

The Los Angeles Rams have partnered with Genius Sports to enhance fan experience at SoFi Stadium with augmented in-game highlights using Next Gen Stats. Verizon will sponsor the content, integrating their brand into the experience.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:20 pm

WLDN

Willdan Group, Inc. has been awarded a four-year contract by the City of Seattle to implement the Seattle City Light Energy Design Assistance Program. The contract involves providing technical assistance for energy-efficient design in new buildings and partnering with local women- and minority-owned businesses.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:18 pm

AVAV

AeroVironment has been awarded a $54.9 million delivery order by the U.S. Army for the production of Switchblade loitering munition systems, with a potential contract ceiling of $743 million. This contract supports the U.S. Army and allied partners.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 1:17 pm

SHIBUSD

Shiba Inu (SHIB) has seen a significant increase in its burn rate, leading to speculation of a potential price rally. The burn rate has increased by over 14,575%, and SHIB's price has risen by 2.6% in the past 24 hours. Key resistance levels have been identified, and if surpassed, SHIB could see a 49% increase. Despite a decrease in large transaction volume, daily active addresses have risen, indicating strong interest in SHIB as a long-term investment.

Portfolio Pulse from Khyathi Dalal

October 14, 2024 | 1:16 pm